Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by abnormal blood vessel growth, leading to recurrent bleeding and anemia. It affects approximately 1 in 5000 people and is inherited in an autosomal dominant manner.
Background
HHT is the second most common inherited bleeding disorder, making its recognition and management crucial for affected individuals. The condition can lead to serious complications, including bleeding from arteriovenous malformations (AVMs) in vital organs. Early diagnosis and intervention are essential to mitigate risks associated with this disorder.
Data Highlights
No numerical data available in the source material.
Key Findings
HHT is caused by mutations in the ENG, ACVRL1, or SMAD4 genes.
About 90% of individuals with HHT experience recurrent nosebleeds, typically starting between ages 10-15.
Patients may develop telangiectasias on the skin and mucous membranes, which can bleed.
Low iron levels and anemia are common due to frequent bleeding episodes.
HHT is inherited in an autosomal dominant pattern, with a 50% chance of transmission from an affected parent.
Clinical Implications
Healthcare providers should be vigilant in recognizing symptoms of HHT, particularly in patients with a family history of bleeding disorders. Genetic testing and regular screening for AVMs are recommended to prevent severe complications. Management strategies should focus on controlling bleeding and monitoring for anemia.
Conclusion
HHT is a significant hereditary condition that requires awareness and proactive management to prevent complications. Understanding its genetic basis and clinical manifestations is essential for effective patient care.
